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INTRODUCTION 
Innate immunity relies on the detection of danger- and pathogen associated molecular 
patterns and a prompt or quick response to maintain the homeostasis of the host. Several 
families of secreted or cellular pattern-recognition receptor molecules - including receptor for 
advanced glycation end products (RAGE), Toll-like receptor family, Nod-like receptors and 
Rig-I-like receptors - are able to sense endogenous danger signals or invading pathogens. 
Activation of these receptor molecules leads to a multistep cascade including nuclear factor-
κB, mitogen-activated protein kinases, and type I interferon response resulting in production 
of mediators of inflammation and antimicrobial defense molecules and/or alarmins. Among 
the latters, different types of defensins can be regarded as the main effector molecules of 
mucosal immune system. 
The receptor for advanced glycation end products (RAGE) is a member of 
immunoglobulin superfamily of cell surface molecules. RAGE binds advanced glycation end 
products, but also, a wide scale of endogenous alarmin molecules that are emerged from 
dying host cells into the extracellular spaces upon microorganism-induced or other type of 
cell damages, such as ribonucleic and deoxyribonucleic acid, amphoterin, ß-sheet fibrils and 
S100 proteins. The ligand/RAGE interactions and the resulting RAGE upregulation are 
believed to activate many cell signaling pathways, leading to enhanced production of reactive 
oxygen species and proinflammatory cytokines. Due to its broad spectrum of sensed 
molecular patterns, RAGE may contribute to the pathogenesis of several multifactorial 
diseases. Three single nucleotide polymorphisms (SNPs) have been highlighted including two 
common functional SNPs (−429T/C [rs1800625] and −374T/A [rs1800624]) in the promoter 
region and a common coding change of a glycine to serine at amino acid 82 (G82S or 
Gly82Ser [rs2070600]). The −429T/C and −374T/A SNPs have been revealed to have effects 
on transcriptional activity. The G82S SNP influences the AGE-binding domain, and the 
RAGE 82S allele up-regulates the binding of S100/calgranulins. The expression of RAGE is 
increased in neurodegenerative diseases, therefore we investigated the relevance of SNPs of 
RAGE promoter in the risk of multiple sclerosis. 
The NLR (Nod-like receptor) family has more than 20 members including nucleotide-
binding oligomerization domain containing protein 1 and 2 (NOD1 and NOD2). These 
cytosolic receptors are essential in sensing intracellular microbial components. NOD1 is 
activated by peptides that contain D-γ-Glu-meso-diaminopimelic acid that is derived from 
peptidoglycan present in almost all Gram-negative bacteria, and is produced either during 
synthesis and/or degradation. NOD1 is ubiquitously expressed in various cell types, including 
epithelial cells, antigen presenting cells, human gingival fibroblasts, myofibroblasts, 
astrocytes and microglia. NOD1 participates in the response to Chlamydia, Shigella, 
enteroinvasive Escherichia coli and Campylobacter. The c.796G>A polymorphism of NOD1 
(rs2075820) has been described; it encodes a changed protein, altering a glutamic acid residue 
(E), where the A allele corresponds to the K variation-lysine (E266K). In view of the close 
relation between NOD1 activation and Chlamydia infection, we considered it of interest to 
investigate the genetic polymorphism of NOD1 from the aspect of the development of stroke. 
Any impairment in function of NOD receptors may lead to an increased risk of infection, or 
an inappropriate mucosal defense mechanism. 
Antimicrobial peptides (AMPs) are key components of innate immunity. Activation of 
pathogen associated molecular patterns in various epithelial cells induces anti-bacterial 
responses. The sufficient defensin production are crucial in maintaining effective antibacterial 
defense. Human ß-defensins, important components of host defense at the mucosal surfaces, 
display a broad spectrum of activity against bacteria, fungi and viruses, and also exhibit other 
functions, including potent chemotactic activity toward immature dendritic cells and memory 
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T cells. Human ß-defensins are apparently expressed in epithelial cells of the skin, gut, 
respiratory and urogenital tissue. It is noteworthy that HBD-1 mRNA expression has also 
been detected in pancreatic acinar cells. While human beta-defensin 1 (HBD-1) is produced 
constitutively, HBD-2 is induced by interleukin-1ß, tumor necrosis factor-α and bacterial 
lipopolysaccharide, and by contact with Gram-negative and Gram-positive bacteria, and 
various fungi. Thus, HBD-2 levels are increased in inflammatory disorders, whereas HBD-1, 
being constitutively expressed, may serve as a defense in the absence of inflammation. Three 
frequent single nucleotide polymorphisms at positions c.–20G>A (rs11362), c.–44C>G (rs 
1800972) and c.–52G>A (rs1799946) in the 5’-untranslated region of the DEFB1 gene were 
described. The level of β-defensin expression varies from individual to individual and it has 
been suggested that this variation is due to genetic differences in the genes encoding the 
HBDs. Two types of genetic polymorphisms have been identified in genes encoding 
defensins, copy number variations and single nucleotide poymorphisms. Hollox et al have 
described copy number polymorphisms of the DEFB4 gene, which encodes HBD-2, with 
copy numbers ranging from 2 to 12 per diploid genome. Higher DEFB4 copy numbers 
correlated with higher levels of DEFB4 mRNA expression. Accordingly, it is presumed that 
this polymorphism may be an important component of genetic variation in susceptibility to 
infections. 
Associated diseases 
The adequate function of the components of the innate immunity is crucial in 
maintaining the homeostasis of the host. Genetic polymorphisms in the genes encoding PRRs 
and AMPs altering expressional level or subsequent amino acid sequence may impair their 
functions, and contribute to the pathogenesis of several multifactorial diseases. Examples of 
such diseases that were investigated in our studies are highlighted below. 
Multiple sclerosis (MS), a devastating neuroinflammatory disorder of the central 
nervous system, can be characterized by multiple demyelization foci of the central nervous 
system, which, in the course of the disease, can materialize in different time patterns. The 
main pathological features of the disease are the destruction of the myelin sheaths of the nerve 
fibers, the relative sparing of the axons, and the infiltration of inflammatory cells in a 
perivascular distribution. Although the well-defined autoimmune activities of the different 
types against the central nervous system are of great importance in the course of the disease, 
the pathomechanism and the direct causative factors have not yet been elucidated. There are 
data indicating that changes in the level of the ROS may play roles in the pathomechanism of 
MS. The disease is determined by a combination of exogenous factors and genetic 
background. Immunohistological studies of spinal cord tissue derived from MS patients have 
demonstrated enhanced RAGE expression in neurons and inflammatory cells. 
Stroke is a major health problem worldwide and there is an urgent need for a better 
understanding of its causes and for the prevention of its occurrence. Ischemic stroke is a 
frequent heterogeneous multifactorial disease that is affected by several environmental factors 
and genetic mutations. Chronic infections with certain pathogens, such as Chlamydophila 
pneumoniae, and genetic parameters that influence inflammatory reactions are suggested to 
contribute to the disease. Serological evidence of past infection with C. pneumoniae, a 
common respiratory pathogen, has been claimed to be associated with risk of ischemic stroke. 
The chronic infection of susceptible target cells, especially monocytes and endothelial cells, 
initiates local inflammation, which is important in plaque formation. Chlamydiae induce 
chronic activation of the immune system, but little is known about the mechanisms of C. 
pneumoniae-induced target cell alterations. The cytosolic NOD proteins are molecules that 
have been implicated in intracellular pattern recognition of bacteria such as the obligate 
intracellular Chlamydia. NF-kB activation via NOD1 is crucial in maintaining inflammatory 
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responses and cytokine activation. It is also known that the activation of NOD receptors 
mediates the induction of human beta-defensins in various epithelial cells. NOD1-mediated 
endothelial cell activation by Chlamydophila. pneumoniae was recently demonstrated; 
therefore, appears that NOD1 is a potent innate immune receptor for C. pneumoniae in 
endothelial cells and monocytes. 
Acute pancreatitis (AP) is a disease with a wide spectrum of clinical courses, ranging 
from mild to severe forms, with a high rate of complications and a high risk of lethality. 
Severe AP (SAP) is characterized by various degrees of necrosis of the pancreatic 
parenchyma and by local and systemic complications, such as the systemic inflammation 
response syndrome and multiple organ failure. Bacterial contamination of pancreatic necrosis 
and the ensuing sepsis are the main causes of death in SAP facilitated by gut barrier 
dysfunction and increased intestinal permeability resulting in bacterial translocation through 
the gut. Pancreatic stellate cells (PSCs) are able to recognize pathogen associated molecular 
patterns via their receptors, leading to the activation of signaling pathways and 
proinflammatory responses. Thus, PSCs might play a role in immune function of the pancreas 
through the recognition of pathogen associated molecular patterns. Mucosal epithelial cells 
produce a variety of antimicrobial peptides that protect the mucosal surface against invading 
microbes. Which is certainly important in preventing the bacterial translocation in the case of 
mild pancreatitis. There is evidence that host genetic factors can affect the severity of AP. 
Genes coding for inflammatory cytokines have been reported to act as modifier genes in AP. 
Defensin induction by Chlamydophila pneumoniae 
Chlamydophila pneumoniae, an obligate intracellular parasite and a common cause of 
acute respiratory infection, has a tendency to cause persistent inflammatory diseases such as 
atherosclerosis, which may lead to cardiovascular diseases or stroke. Three principle cell 
types involved in the atherogenic process within the developing atheroma include endothelial 
cells, vascular smooth muscle cells, and monocytes/macrophages. Recent publications have 
indicated that C. pneumoniae infection induces HBD-2 expression in human mononuclear 
cells and in gingival fibroblasts. It has been reported that C. pneumoniae can infect human 
endothelial cells and induce the expression of cytokines, adhesion molecules, chemokines and 
molecules with procoagulant activity. As endothelial cells are related to the physiopathology 
of stroke, we considered it of interest to investigate the effects of in vitro C. pneumoniae 
infection on the HBD-2 expression in brain capillary endothelial cells. 
AIMS 
The genetic variations of pattern recognition receptor molecules and defensins may 
influence the severity and/or the course of multifactorial diseases, such as multiple sclerosis, 
stroke and pancreatitis. Therefore we investigated: 
• Three common genetic polymorphisms of RAGE in patients with multiple sclerosis; 
• The c.796G>A SNP of NOD1 gene was investigated from the aspect of the 
development of ischemic stroke; 
• The relevance of three SNPs in the promoter region of DEFB1, that might be related 
to the development of SAP or to bacterial contamination of pancreatic necrosis, was 
investigated. Accordingly, the copy number variation of DEFB4 gene, that alters the 
level of produced HBD-2 peptide, was studied among patients with acute pancreatitis; 
• As endothelial cells are related to the physiopathology of stroke, we completed our 
studies with the investigation of the effects of in vitro infection with Chlamydophila 
pneumoniae on the expression of human beta-defensin 2 in human brain capillary 
endothelial cells. 
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PATIENTS AND METHODS 
Patient group with multiple sclerosis and controls 
One-hundred and fifty four relapsing-remitting and 14 secondary progressive type MS 
patients were included in the study. The clinical inclusion criterion was a diagnosis of 
clinically definitive MS (Poser criteria). The control group consisted of 136 age- and gender 
matched healthy blood donors. 
Patient group with acute ischemic stroke and controls 
A total of 280 patients with acutely developing ischemic stroke, who had never 
suffered a previous stroke event, were involved in the study. All sera from ischemic stroke 
patients (from either patients or controls) were tested for Chlamydophila pneumoniae IgG. 
The control group consisted of 150 age- and gender matched healthy blood donors. 
Patient group with acute pancreatitis and controls 
One-hundred and twenty-four patients with acute pancreatitis were enrolled in our 
study, 30 of them suffered from the mild and 94 from the severe form of the disease, 
classified according to the original criteria of Ranson. The control cohort consisted of 
random, unrelated population of 100 healthy blood donors, who did not have any 
gastrointestinal and/or liver diseases. 
DNA extraction 
For the detection of various genetic polymorphisms genomic DNA was purified from 
peripheral whole blood. The leukocyte DNA was isolated according to the manufacturer’s 
instructions. And stored at -20°C until further use. 
Determination of RAGE SNPs 
Restriction fragment length polymorphism (RFLP) assays were used to detect the 
−429T/C, −374T/A, and the G82S SNPs of RAGE. After the amplification the PCR product 
was digested with AluI restriction endonuclease for −429T/C and G82S and with TasI for 
−374T/A. The restriction products were separated by electrophoresis in 3% agarose gels and 
visualized in UV light after gel red staining. 
Determination of c.796G>A polymorphism of NOD1 
The 796G-to-A transition in exon 3 was analyzed by PCR-RFLP. To digest the PCR 
products AvaI restriction enzyme was used, then electrophoresed on 2% agarose gel, 
visualized under UV illumination and stained with 0.4 mg/l ethidium-bromide. The presence 
of a AvaI site (G allele) was indicated by cleavage of the 379 bp amplified PCR product to 
yield fragments of 209 and 170 bp. 
Determination of DEFB1 SNPs 
Genotyping was performed using Custom TaqMan® SNP Genotyping Assays. 
Fluorogenic minor groove binder probes were used for each cases using FAM and VIC dyes 
to determine the genotypes of DEFB1 c.-20G>A, c.-44C>G and c.-52G>A. Thermal cycling 
was performed on ABI Prism 7000 sequence-detection PCR systems. Initial and post-assay 
analysis was performed using the Sequence Detection System (Applied Biosystems) as 
outlined in the TaqMan Allelic Discrimination Guide. 
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Determination of DEFB4 gene copy number 
A TaqMan® real-time PCR assay, specifically for amplification of genomic DEFB4, 
was established by using a specific set of amplification primers and a VIC-labeled probe. 
Quantitative DEFB4 amplification data were normalized to FAM-labeled albumin as an 
internal reference gene, which was co-amplified simultaneously in a single tube biplex assay. 
Quantification was performed by the comparative threshold cycle (CT) method. 
Cell line and in vitro infection with Chlamydophila pneumoniae 
BB19 cells, human brain capillary endothelial cell line was cultured as monolayer 
culture and infected in vitro with Chlamydophila pneumoniae CWL-029 respiratory and CV6 
cardiovascular strain at a multiplicity of infection of 5 IFU/cell. Control cells were not 
infected, or were treated with the same volume of mock prepartions. In addition to infection 
with viable C. pneumoniae, BB19 cells were stimulated with organisms that had been 
previously heat-inactivated. The plates were incubated at 37°C under 5% CO2, and infected 
and control cells were harvested at the times indicated. 
RNA isolation from BB-19 cell lysates and PCR amplification 
Total RNA was isolated from cell lysates and complementary DNA (cDNA) was 
generated. After reverse transcription, real-time PCR analyses were performed in a 
fluorescence temperature cycler (LightCycler; Roche Diagnostics GmbH, Mannheim, 
Germany) according to the manufacturer’s instructions. Cycle-to-cycle fluorescence emission 
readings were monitored and analyzed using LightCycler software (Roche Diagnostics). 
Melting curves were generated after each run to confirm amplification of specific transcripts. 
Relative gene expression is given as a ratio between target gene and GAPDH gene 
expressions. 
Western blot assays  
BB-19 cells were homogenized and centrifuged to remove cell debris. Protein 
concentrations of cell lysates were determined using the Bio-Rad protein assay. To detect 
beta-defensin, aliquots were resolved by SDS-PAGE and electrotransferred onto 
polyvinylidene difluoride membranes (Bio-Rad). Preblocked blots were reacted for 4 h with 
specific polyclonal antibodies to human b-defensin 2 (RD Systems, Minneapolis, MN, USA). 
Blots were then incubated for 2 h with species-specific secondary antibody coupled to 
peroxidase. Filters were washed five times in PBS-Tween for 5 min after each step and were 
developed using a chemiluminescence detection system (Amersham, Buckinghamshire, UK). 
Human ß-defensin 2 ELISA 
For direct testing of the presence of the HBD-2 peptide in the infected and uninfected 
brain capillary endothelial cells, and for measurement of the secreted HBD-2 protein into the 
tissue culture medium, a sensitive HBD-2 ELISA (Alpha Diagnostic, San Antonio, TX, USA) 
was used according to the manufacturer’s instructions. The detection limit of this ELISA kit 
was 0.8 pg/HBD-2 protein/ml. 
Immunofluorescent Assay 
Expression of HBD-2 peptide by Chlamydophila pneumoniae infected and non-
infected BB19 cells were investigated by immunofluorescence analysis. Cells were fixed and 
stained with goat anti-HBD-2 antibody (RD Systems). Bound antibody was detected with 
FITC-conjugated rabbit anti-goat IgG (Sigma). Fluorescence signals were analyzed via 
confocal laser scanning microscopy. The immunofluorescence of control and C. pneumoniae 
infected cells was quantitatively analyzed. 
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Statistical analysis 
Statistical analyses for comparison of genotype frequencies between groups were 
performed by using the χ2 (chi-square) test, and Fisher's exact test if one cell had n < 5 with 
the probability level of p<0.05 indicating statistical significance. The relationship between 
genotypes and disease severity is presented as the odds ratio (OR), with a 95% confidence 
interval (CI).The genotype frequencies for each polymorphism were tested for deviation from 
the Hardy-Weinberg equilibrium by means of the χ2 test, with one degree of freedom used. 
Statistical calculations were performed with the Graph Pad Prism 5 (Graph Pad Software Inc., 
San Diego, CA) statistical program. For the quantification of HBD-2 expression using RT-
PCR and ELISA, all values are expressed as mean ± SD. The data were subjected to two-
tailed paired Student’s test. For all statistical evaluations, p<0.05 was considered statistically 
significant. Data analyses were performed by Graph PadPrism 5 statistical program. 
RESULTS 
RAGE −374T/A polymorphism in patients with sclerosis multiplex 
The distribution of the genotypes was in accordance with the Hardy–Weinberg 
equilibrium both in the control group and in the MS patients (p=0.975 and 0.999, 
respectively). There was a significant difference in genotypes between the patients and 
healthy controls (χ2 test, p=0.003). It was a lower frequency of the AA genotype among the 
patients with MS as compared with controls: 14 of the 168 patients (8%) versus 25 of 131 
healthy controls (19%); OR=2.75 vs. controls, 95% CI=1.319-5.733, p=0.007. Conversely, a 
higher frequency of TT genotype was observed among MS patients (84/168=50%) than 
among in controls (43 of 131=33%; OR=2.22 vs. controls, 95% CI=1.322−3.747, p=0.003). It 
is noteworthy that none of the 14 patients with secondary progressive type MS carried the AA 
genotype. 
RAGE −429T/C polymorphism in patients with sclerosis multiplex 
The distribution of the genotypes was in accordance with the Hardy–Weinberg 
equilibrium both in the control group and in the MS patients (p=0.646 and p=0.323, 
respectively).There was no significant difference in the −429T/C genotypic distribution 
between the patients with MS and the healthy controls. 
RAGE G82S polymorphism in patients with sclerosis multiplex 
One hundred eight DNA samples from the control group and 103 samples from the 
MS patients were further available for investigation of the G82S SNP. The distribution of the 
genotypes was in accordance with the Hardy–Weinberg equilibrium both in the control 
population (p=0.976) and in the patients with MS (p=0.970). There was no significant 
difference in the G82S genotypic distribution between the patients with MS and the healthy 
controls We could not detect the SS homozygote genotype in either the controls or the MS 
group. The frequencies of the GG and GS genotypes were similar in the two groups. 
NOD1 c.796G>A polymorphism among Chlamydophila pneumoniae seropositive stroke 
patients 
The distribution of the NOD1 genotypes was in accordance with the Hardy–Weinberg 
equilibrium both amongst the control population (χ2=0.98, p=0. 322) and amongst the patient 
group (χ2=1.55, p=0.213). There was no significant difference in the genotype distribution 
between the patients overall and the healthy controls (χ2=4.2, p=0.121). When the 
Chlamydophila pneumoniae seropositivity was taken into account, a considerable difference 
in frequency of the NOD1 polymorphism was observed between the overall group of C. 
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pneumoniae-positive patients and C. pneumoniae positive controls (χ2 =21.813, p<0.001). No 
significant difference was observed; however, between the NOD1 genotypes of controls and 
patients amongst the C. pneumoniae-negative groups. The AA homozygote and GA 
heterozygote mutant variants were detected in 16% (25 of 152) and in 51% (77 of 152) of the 
C. pneumoniae-positive stroke patients, as compared with 7% (6 of 84), and 29% (24 of 84), 
respectively, in the C. pneumoniae-positive healthy controls. (OR=2.559; 95% CI=1.105–
6.517, p=0.04, and OR=2.56795% CI=1.451–4.540; p<0.001, respectively). The frequency of 
A allele was 42% in C. pneumoniae positive stroke patients, whereas it was only 21% in C. 
pneumoniae positive controls. The difference in genotype amongst C. pneumoniae positive 
subjects was more striking, when the patients were stratified into the small vessel and large 
vessel groups. Those in large vessel group displayed the highest frequency of the mutated 
allele A (51%). The frequency of the GA genotype was 56% (37 of 66) amongst the 
Chlamydophila-positive stroke patients with large vessel disease, which means an OR of 3.19, 
95% CI: 1.618–6.288, p=0.0008, as compared with the Chlamydophila-positive control 
subjects (24 of 84; 29%). The difference in the frequency of AA homozygotes was even 
higher amongst these groups, with an OR of 3.824; 95% CI: 1.362–10.50, p=0.008. 
Conversely, the prevalence of the GG, wild type genotype was significantly lower in the 
group of patients with the large vessel pathology, than in the controls and those with small 
vessel disease; 21% (14 of 66) vs. 64% (54 of 84) and 42% (36 of 86), respectively. 
(OR=0.162, 95% CI: 0.076–0.341, p<0.001; and OR=0.405, 95% CI: 0.194–0.843, p=0.021, 
respectively.) In contrast, the difference in the genotype frequencies between the stroke 
patients with small vessel disease and the controls was less marked; considering the GA 
genotype, there was an OR of 2.177; 95% CI: 1.510– 4.104, p=0.01; and there was no 
significant difference in the frequency of the AA genotype, i.e., 11% (10 of 86) vs. 8% (6/84), 
p=0.43. Therefore, we conclude that the SNP of the NOD1 c.796G>A gene is significantly 
higher amongst Chlamydophila positive stroke patients, and the highest frequencies of the GA 
and AA genotypes are to be observed amongst those patients, with large vessel disease. In 
other words, Chlamydophila positivity with polymorphism of the NOD1 c.796G>A gene is a 
higher risk factor for the development of stroke with large vessel disease than with small 
vessel disease. Interestingly, amongst the C. pneumoniae negative patients, no significant 
difference in genotype frequency was observed between the patients with large vessel disease 
and those with small vessel disease. 
DEFB1 c.-20G>A polymorphism in patients with acute pancreatitis 
The distribution of the DEFB1 c.-20G>A genotypes was in accordance with the 
Hardy-Weinberg equilibrium in the control population (p=0.996, χ2=0.001) and also in the 
patient group (p=0.665, χ2=0.199). There was a significant difference in genotype distribution 
between the pancreatitis patients overall and healthy controls (p=0.03). When the patients 
were stratified according the disease severity, a more significant difference was observed only 
between the controls and the patients with severe pancreatitis (p=0.009), but not between the 
controls and patients with mild pancreatitis (p=0.44), when the genotypes were taken into 
consideration. Thereafter we compared the numbers of AA homozygotes among the patients 
with severe pancreatitis and the controls. There was a higher frequency (38%) of the AA 
genotype among the patients with severe disease as compared with the controls (20%); 
OR=2.48, 95% CI: 1.305-4.722, p=0.006. The highest frequency of AA genotype was 
observed among patients with infected pancreatic necrosis (61%). The carriage of the A allele 
was also significantly different between the patients with SAP (63%) and the healthy blood 
donor group (44%). Conversely, the prevalence of the DEFB1 c.-20 GG wild type genotype 
was significantly lower (11%) in the group of patients with severe acute pancreatitis than in 
the healthy control group (31%). 
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DEFB1 c.-44C>G polymorphism in patients with acute pancreatitis 
The distribution of DEFB1 c.-44C>G genotypes was in accordance with the Hardy-
Weinberg equilibrium among the patients with acute pancreatitis (p=0.610, χ2=0.260) and also 
in the control population (p=0.597, χ2=0.279). There was a significant difference in genotype 
distribution between the patients overall and the healthy controls (χ2 test, p=0.02). When the 
patients were stratified according the disease severity, a significant difference was observed 
only between the controls and patients with severe pancreatitis (p=0.03) and not between the 
controls and patients with mild pancreatitis, (p=0.84). Interestingly, there was a lower 
frequency of the GG genotype among the patients with pancreatitis as compared with the 
controls: 2 of the 124 patients with acute pancreatitis (1%) and none of patients with severe 
acute pancreatitis (0%) vs. 9 of the 100 healthy controls (9%). Conversely, the prevalence of 
the DEFB1 CC genotype was 72 % in the group of patients with severe acute pancreatitis vs. 
56 % of controls; Fisher test: p=0.02, OR=2.055, 95% CI: 1.27 – 3.745. 
DEFB1 c.-52G>A polymorphism in patients with acute pancreatitis 
The distribution of the DEFB1 -52 genotypes was in accordance with the Hardy-
Weinberg equilibrium in the control population (p=0.502, χ2=0.250) and also in the patient 
group (p=0.997, χ2=0.0001). There was a significant difference in genotype distribution 
between the pancreatitis patients overall and healthy controls (p=0.004). When the patients 
were stratified according the disease severity, a more significant difference was observed 
between the controls and patients with severe pancreatitis. (p=0.001) and not between the 
controls and patients with mild pancreatitis, (p=0.606) when the genotypes were taken into 
consideration. There was a higher frequency (41%) of the AA genotype among the patients 
with severe disease as compared with the controls (18%); OR=3.23, 95% CI: 1.678–6.218, 
p=0.0005. The carriage of the A allele was also significantly different between the patients 
with severe pancreatitis (64%) and the healthy blood donor group (39%,). Conversely, the 
prevalence of the DEFB1 c.-52 GG wild type genotype was significantly lower (14%) in the 
group of patients with severe acute pancreatitis than in the healthy control group (40%). 
Copy number polymorphism of human beta-defensin-2 in patients with acute 
pancreatitis 
In the control group the copy numbers had a range of 2-10 per genome, with a median 
number of 4 copies. The proportions of control individuals who carry the median (4), less 
than median (<4) or more than median (>4) number of copies were 24% , 40% and 36% 
respectively. In patients with acute pancreatitis the frequency distribution of the subgroups 
was significantly different from that of the control group (p=0.001). 42% of patients with 
acute pancreatitis overall had a lower copy number <4, while in patients with severe acute 
pancreatitis the frequency of a low copy number (<4) was 62%, and that of a copy number >4 
was only 10%. 
Expression of human ß-defensin 2 mRNA in BB19 cells and increase in expression by 
Chlamydophila pneumoniae 
To determine whether HBD-2 gene expression is induced in BB19 cells in response to 
C. pneumoniae infection, RT PCR was performed. A time-dependent increase in HBD- 2 
mRNA was observed in BB19 cells. The maximum increase in HBD-2 mRNA expression 
was observed at 24 h at a MOI of 5 IFU. The infection of endothelial cells by CV6, a 
cardiogenic strain, resulted in a more pronounced expression of HBD-2 mRNA. We 
compared the effects of heat-inactivated C. pneumoniae with those of viable C. pneumoniae. 
In cells stimulated with heat-inactivated C. pneumoniae, the expression of HBD-2 was 
induced, although at a reduced level. Mock preparations did not result in any increase in 
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HBD-2 mRNA. We tested also the constitutive HBD-1 expression in BB19 cells. In contrast 
to HBD-2, there was no any increase in expression of HBD-1 mRNA following C. 
pneumoniae infection. 
Human ß-defensin 2 protein expression in BB19 cells infected with C. pneumoniae 
The expression of HBD-2 protein in C. pneumoniae infected endothelial cells was 
determined by immunoblotting. Through use of the anti-HBD-2 antibody which binds to 
human HBD-2, a single band of about 4 kDa was detected. The signal was strong following 
the blotting of cell lysates from C. pneumoniae-infected cells. The level of HBD-2 was only 
barely detectable after the processing of the control cell lysate without C. pneumoniae 
infection. 
Immunofluorescent staining of BB19 cells for HBD-2 
Immunofluorescent staining images of C. pneumoniae infected BB19 cells revealed 
that HBD-2 was diffusely distributed as granules throughout the cytoplasm of the endothelial 
cells. There was only a weak fluorescence in the uninfected controls. The calculated 
fluorescence intensity mirrored the ELISA and Western blotting results, indicating that the 
HBD-2 protein was highly inducible. 
Chlamydophila pneumoniae induces HBD-2 secretion by BB19 cells 
Experiments were performed to determine the HBD-2 protein secreted by BB19 cells 
into the tissue culture medium following C. pneumoniae infection. The amount of HBD-2 in 
the supernatants was determined by ELISA. Results of these experiments showed that the 
concentration of HBD-2 protein was significantly elevated in the supernatant 24 h after C. 
pneumoniae infection. The supernatants from BB19 cells stimulated with heat-inactivated C. 
pneumoniae displayed a moderate release of HBD-2 peptide. The BB19 cells incubated with 
mock stocks exhibited a similar level of HBD-2 release as that of the noninfected controls 
(data not shown). In parallel experiments, the concentration of HBD-2 was also determined in 
the cell lysates. A considerable increasing the amount of HBD-2 was detected in the cell 
lysates of cultures infected with C. pneumoniae CWL-029 or with C. pneumoniae CV6 for 24 
h (35.2 ± 3.8 pg/ml and 48.4 ± 4.6 pg/ml, respectively, vs 5.5 ± 2.8 pg/ml in the control cell 
lysates). These results imply that human endothelial cells stimulated by C. pneumoniae induce 
the expression of the HBD-2 gene and the release of HBD-2 protein into the medium. 
DISCUSSION 
RAGE Gene Polymorphisms in Patients with Multiple Sclerosis 
The up-regulation and pathogenic effects of RAGE in MS highlight the RAGE gene as 
a candidate for involvement in the pathogenesis of the disease. Our results have demonstrated 
an association between the −374T/A polymorphism of the RAGE promoter and MS; the 
frequency of the AA genotype was significantly higher in the control group than in MS 
patients, suggesting that the AA genotype may have a protective role against the development 
of MS. There was no significant difference in genotype between men and women nor in 
genotype distribution if the patients were stratified overall according to the severity of the 
disease. However, it is noteworthy that none of the patients with the SP type of MS exhibited 
the AA genotype, though the number of these patients in our study was low (14). Therefore, 
we presume that the −374T/A polymorphism of RAGE is a risk factor for MS in general and 
influences the development of the secondary relapsing form of the disease rather than simply 
the severity. The −374T/A polymorphism of RAGE gene located in the promoter region of 
the gene has previously been shown to exert significant effects on transcriptional activity. Our 
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results raise the question of how the altered transcription of the RAGE promoter region can 
affect the risk of MS. We presume that altered transcription may lead to a reduced degree of 
expression of the RAGE, which could limit the activation of multiple RAGE-mediated 
signaling pathways, leading to a different level of susceptibility to MS. There was no 
difference in frequency of −479T/C genotype between the MS patients and the controls. In 
accordance with this result, the study of Hudson et al. did not reveal any clear differences in 
actual protein–DNA interactions in the case of the −429T/C polymorphism, but a very distinct 
difference in transcription factor binding was observed between the −374T and A alleles. The 
T to A substitution appeared to prevent the binding of nuclear factor, which suggested that a 
disruption of nuclear protein is involved in repression of RAGE transcription. Transcription 
factor binding assays revealed the abolition of a nuclear protein binding site with the 
introduction of the −374A allele, supporting the role rather of this polymorphisms and not of 
−429T/C in affecting RAGE transcription repression. As concerns the Gly82→Ser 
polymorphism, Ser82 enhances receptor signaling through mitogen activated protein kinases 
and nuclear factor of kappa B. However, the RAGE Gly82→Ser polymorphism showed no 
association with MS in our study. Hence, we assume that inhibition of the expression of 
RAGE itself and not the modulation of signaling may be a definitive factor in MS. In 
conclusion, we suppose that the altered transcription induced by the −374T/A SNP could lead 
to a reduced level of RAGE, which might be a factor protecting against the development of 
MS. Our findings support the view that RAGE plays a role in the development of MS. Further 
studies will elucidate whether blockade of RAGE has a therapeutic potential for the 
prevention of brain tissue injury and neurodegeneration in MS. 
Relevance of the genetic polymorphism of NOD1 in Chlamydophila pneumoniae 
seropositive stroke patients 
The causation of ischemic stroke is multifactorial a combination of genetic risk factors 
and environmental factors. Inflammatory parameters and chronic and acute infectious diseases 
have been considered to modify stroke risk independently of conventional risk factors. Sero-
epidemiological studies are limited by the high prevalence of antibodies in adults. The risk 
due to a prior infection may be influenced by individual inflammatory response of the host. 
Toll-like receptors and NOD proteins are pattern recognition receptors, which are key 
elements in the regulation of immune response. TLR4 is the transmembrane 
lipopolysaccharide receptor, which initiates the innate immune response to Gram-negative 
bacteria, including Chlamydophila pneumoniae. To check the importance of the difference in 
NOD1 genotype, we investigated the NOD1 SNP in stroke patients. Several SNPs in NOD1 
has been described The G796A SNP was chosen in the coding sequence of the gene in exon 3, 
as it was earlier reported to encode a changed protein, (E266K) in the nucleotide binding 
domain altering a glutamic acid residue, suggesting a potential functional effect of the 
mutation. It was recently found, that the NOD1 A allele is associated with reduced expression 
of NOD1 protein, leading to diminished NF-kB activation in response to Propionibacterium 
acnes. It is suggested that the E266K substitution reduces the stability of NOD1. In addition 
to the induction of cytokines, NOD activation may be involved in signaling cascade-mediated 
defensin expression. Any failure in the production of this natural antibacterial protein could 
lead to an imbalance between invading bacteria and the host innate immunity. Thus, an 
impaired defensin synthesis might be linked to a higher rate of multiplication of invading 
bacteria. In our study, the NOD1 genetic polymorphism appeared to be a potential risk factor 
in ischemic stroke only in C. pneumoniae-infected patients. In other words, it may be 
speculated, that in the case of C. pneumoniae infection, a functional deficiency of the NOD1 
signaling system could lead to a higher rate of multiplication of Chlamydophila and to a more 
intensive local inflammatory response. Conversely, C. pneumoniae infection alone, with an 
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appropriate immune response is not enough for a definitive inflammatory induction, and 
plaque formation in the blood vessels. This seems to be supported by the fact, that the 
proportion of Chlamydophila positivity was not significantly higher in our stroke patients. 
The results of the serological examinations are in contrast with the observation underlining 
the association with C. pneumoniae seropositivity in stroke. In this sense, our results are in 
agreement with the finding of no association of C. pneumoniae antibodies with ischemic 
stroke. However, we did detect a significant association between the SNP of NOD1 receptor 
(which also detects C. pneumoniae) and stroke only in C. pneumoniae-positive patients. To 
the best of our knowledge, this is the first report concerning the relevance of NOD1 
polymorphism in the risk of ischemic stroke amongst Chlamydophila-positive patients. There 
were significant differences in NOD1 G796A genotype distribution between the controls and 
the stroke patients with C. pneumoniae infection. In the interpretation of our data, some 
limitations should be considered. The small number of subjects in our preliminary study is an 
indication of a need for caution. For a stronger power, the number of patients in each group 
should be increased appreciably, which requires a multicenter approach. There is certainly no 
specific link between any chronic infectious disease and stroke, but it appears much more 
probably that the chronic infections are risk factors that act in cooperation with conventional 
risk factors and genetic predisposition, which are neither necessary nor sufficient for disease 
generation alone. Polymorphism in NOD1 E266K is not a risk factor for stroke in general, but 
in association with C. pneumoniae infection it appeared to be accompanied by an increased 
risk of the development of stroke; therefore, it could prove to be a valuable marker for an 
assessment of the risk of stroke in combination with C. pneumoniae infection. 
Relevance of genetic polymorphisms of beta-defensins in severe acute pancreatitis 
Maintenance of the integrity of the gut barrier is one of the goals in the treatment of 
severe acute pancreatitis. For this reason, enteral nutrition has been proposed for restoration 
and prevention of the morphological changes in the gut associated with fasting. More 
recently, another method involving the use of probiotics has been proposed to reduce the 
infection of necrosis by intestinal bacteria. Apart from a direct or indirect action on other 
bacteria, it is believed, that probiotics act directly on the mucosal immune system, stimulating 
an increased production of β-defensins. On the basis of  these observations, we presumed, that  
an investigation of the relevance of genetic polymorphisms of beta defensins in acute 
pancreatitis was plausible. We supposed that any decrease in defensin expression either in the 
colonic mucosa or locally in the pancreatic tissue could result a higher rate of bacterial 
translocation from the gut, or even an increased possibility of retrograde infection. The 
expression of HBD-1 mRNA in the pancreas acinar cells suggest that HBD-1 fulfills 
physiological functions in the host defense. Our analysis of DEFB1 c.-20G>A genotypes 
among patients with AP revealed that the AA genotype comprises a higher risk of severe form 
of disease (OR=2.48 ). The functional significance of this SNP resides in the formation of a 
nuclear factor-kappa B transcription factor-binding sequence, and it likely that this mutation 
might cause a lower hBD1 expression in colonic epithelial cells or in pancreatic acinar cells. 
Similarly, the G/A SNP at the -52 region of DEFB1 correlates with decreased expression of 
HBD-1 and this is in accordance with our results demonstrating a higher frequency of the A 
allele in patients with SAP. It is tempting to speculate that this mutation in the -52 
untranslated region might cause a lower HBD-1 expression in epithelial cells with a deficient 
function of human defensin. It is noteworthy, that 29 of the 94 patients in the SAP group 
suffered from infected necrosis with multiple organ failure, and 25 of  them carried the  A 
allele of  c.-20G>A. Similarly, concerning the c.-52G>A SNP, 27 of the 29 patients carried 
the mutant A allele. We therefore presume that individuals displaying the presence of the 
polymorphism may be predisposed to the most severe complications of acute necrotizing 
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pancreatitis. The present study has demonstrated that the distributions of c.-44C>G 
polymorphism were different in the patients with SAP and the healthy controls, while the 
frequency of the GG genotype was significantly higher in the controls. This result indicates 
that the C/G mutation probably leads to strengthened HBD1 antimicrobial activity, which is 
less frequent among patients with SAP. The SNP at -44C>G generates a putative binding site 
for nuclear factor-kB, and induces overexpression.These data are consistent with our present 
observation that the GG phenotype could also be protective in acute pancreatitis. Again, 
among the 29 patients with infected  necrotic pancreatitis only 5 carried the G allele, or 
protective allele, and none of them was GG homozygote. These observations draw  attention 
to the importance of DEFB1 polymorphism especially as concerns a predisposition to infected 
pancreatic necrosis. In the present study, acute pancreatitis was characterized by a shift to 
lower copy numbers of DEFB4 encoding HBD-2. A low beta-defensin gene copy number in 
Crohn’s disease predisposing to colonic localization has been reported, most  likely through 
diminished beta-defensin expression. Similarly, we suppose, that in our study individuals with 
< 4 copies are at a higher risk of developing severe acute pancreatitis because of .an impaired 
HBD-2 expression rate. To the best of our knowledge, this is the first time that three DEFB1 
SNPs have been tested for a possible association with acute pancreatitis. The DEFB1 G-20A 
and DEFB1 C-44G and DEFB1 G-52A SNPs differed between the patients with SAP and the 
healthy controls. Additionally, the low copy number of DEFB4 - the gene of human defensin 
β-2 - in patients with SAP draws attention to the importance of defensins in development of 
severe form of AP. Our results should be regarded as preliminary results, indicating the 
relevance of the SNPs in the genes encoding HBD1 and HBD2 in acute pancreatitis and 
especially in infected SAP, which should be confirmed on a larger series of  patients in a 
future multicentre study. Although the SNP may be only one of the factors that contribute to 
the susceptibility to SAP, our data further support the idea, that SAP could be due also to the 
defective production of beta-defensins It is unlikely that a single modifier gene alone is 
responsible for SAP. It is more likely, that the combination of a multitude of SNPs, in 
different genetic loci and genes, contribute to produce the clinical phenotype of SAP. The 
identification of the variants of the DEFB1 and DEFB4 genes may contribute to a better 
understanding of the pathogenesis of this disease. 
Inducible expression of human ß-defensin 2 by Chlamydophila pneumoniae in brain 
capillary endothelial cells 
Expression of defensins in human endothelial cells in response to C. pneumoniae has 
not been studied previously. Sero-epidemiological studies in patients with stroke have 
provided evidence of an association of risk with prior infection with C. pneumoniae. The 
endothelial dysfunction observed in stroke patients has been related to the physiopathology of 
stroke, the stroke subtypes, the clinical severity and the outcome. The present study was 
performed to analyze the expression of HBD-2 and the effects of C. pneumoniae on HBD-2 
expression in the human brain capillary endothelial cell line BB19. Human ß-defensin 2, an 
antimicrobial peptide, has so far been found exclusively in a variety of epithelial cells. No 
data are available on HBD-2 expression in endothelial cells except for the very recent 
publication by Kawsar et al., which reported the expression of HBD-2 in the intratumoral 
vascular endothelium and HUVECs (human umbilical vein endothelial cells). In our study, 
the expression of HBD-2 mRNA in brain capillary endothelial cells was first assessed by RT-
PCR. As mRNA may not always be translated to protein, we also investigated whether 
capillary brain endothelial cells express the HBD-2 peptide. The expression of the HBD-2 
peptide in endothelial cells was confirmed by immunofluorescence staining for HBD-2 
peptide and by Western blotting. The secretion of HBD-2 was confirmed by measuring the 
HBD-2 in the supernatants by ELISA. In good accordance with the inducible nature of HBD-
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2 in keratinocytes and epithelial cells, we observed a definite increase in the expression of 
HBD-2 upon exposure to C. pneumoniae. In our experiments, heat-inactivated C. pneumoniae 
was still able to induce the expression and secretion of HBD-2, albeit at lower levels. This 
suggests that, among the potential products of bacteria, one candidate could be a heat-resistant 
lipopolysaccharide. On the other hand, heat–labile compounds, such as outer membrane 
proteins or other yet unidentified factors, might also be candidates for HBD-2 activation. 
Infection of human endothelial cells with C. pneumoniae results in the stimulation of a wide 
variety of cytokines, adhesion molecules, chemokines and proteins with procoagulant activity, 
which furnishes evidence of the role of infection with this bacterium in the atherogenic 
process. The role of ß-defensin peptide in endothelial cell biology is not clear. It might be that 
endothelial cells use defensins to exert antimicrobial activity. Defensins also exert a broad 
spectrum of immunological effects; human ß-defensins may attract immature dendritic cells, 
naive T-cells and memory T-cells, which suggests that these defensins are involved in 
orchestrating an immune response, and it may be hypothesized that HBD-2 contributes to the 
possible innate immunity involved in atherosclerosis. Further studies are necessary to 
elucidate the role of HBDs in atherosclerosis or stroke. The result demonstrating that HBD-2 
is expressed and produced in the human brain capillary endothelial cells upon infection with 
C. pneumoniae is novel and provides evidence that HBD-2 plays a role in the early immune 
responses to C. pneumoniae and probably in the immunopathogenesis of atherosclerosis. This 
result might facilitate an understanding of the pathomechanism of the inflammation-mediated 
events of atherosclerosis or stroke in connection with C. pneumoniae infection. 
SUMMARY AND NEW RESULTS 
1. Our results revealed an association between the -374 T/A polymorphism of the RAGE 
promoter and multiple sclerosis. The genetic variant -374 AA (which has previously 
been shown to exert significant effects on transcriptional activity) can be considered a 
preventive factor as regards the occurrence of MS. Our findings support the view that 
RAGE plays a role in the development of MS. 
2. Polymorphism of NOD1 G796A alone did not prove to be a risk factor for stroke in 
general, but in association with Chlamydophila pneumoniae infection it appeared to be 
accompanied by an increased risk of the development of stroke. 
3. The DEFB1 G-20A and DEFB1 C-44G and DEFB1 G-52A SNPs differed between 
the patients with SAP and the healthy controls. Additionally, the low copy number of 
DEFB4 - the gene of human defensin beta-2 - in patients with SAP draws attention to 
the importance of defensins in development of severe form of AP. The variations in 
the genes encoding human b-defensin-1 and -2 may be associated with the risk of 
severe acute pancreatitis and also with infected acute pancreatitis. 
4. The results of in vitro experiments indicate that human β-defensin-2 is expressed and 
produced in the human brain capillary endothelial cells upon infection with 
Chlamydophila pneumoniae, and provide evidence that HBD-2 plays a role in the 
early immune responses to C. pneumoniae and probably in the immunopathogenesis 
of atherosclerosis. 
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